(CercleFinance.com) – Genfit announces that it recorded a net result of 67.3 million euros for 2021, against a loss of 101.2 million the previous year, and an operating result of 31.8 million euros, compared to a loss of 82.9 million in 2020.
The biopharmaceutical laboratory’s turnover amounted to €80.1 million, mainly including the recognition of a product under the initial payment received from Ipsen pursuant to the license agreement signed in December 2021 .
“We are entering 2022 having made real progress in the Elative trial, and with increased financial visibility which will allow us to enrich our product portfolio and accelerate our current programs”, comments its managing director Pascal Prigent.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
